Pulmonary Fibrosis Patient Dedicates His Last Hours To Sick Children
Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
Pulmonary Fibrosis Patient Dedicates His Last Hours To Sick Children
PFF Care Center Network Expands to 19 New Sites
The Pulmonary Fibrosis Foundation (PFF) recently announced that its PFF Care Center Network has added 19 new sites, almost double its previous number, and now totals 40 centers across 26 U.S. states. The Network, started in 2013, is a group of leading medical centers with specific expertise in the treatment of pulmonary fibrosis (PF), a…
#TBT – Remembering Charlie Boone
Charlie Boone died past Sunday at the age of 88. Boone was the WCCO Radio host who was the voice of mornings in Minnesota for nearly 40 years and one of its stars. “Charlie was one of the greatest talents in the history of radio broadcasting, and…
Types Of Pulmonary Diseases
“Learn what the main classifications of lung diseases are: obstructive, restrictive, ventilation, and perfusion. Discover the classification of common diseases like asthma, emphysema, and pneumonia.” Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
PFF’s Summit 2015 Sets Records for Attendance, Scientific Studies
The recently concluded Pulmonary Fibrosis Foundation (PFF)’s third biennial scientific conference, Summit 2015: From Bench to Bedside, achieved a record attendance of over 700 people — from pulmonary fibrosis researchers, academics and healthcare specialists to industry front-runners and PF patients/caregivers — representing 18 countries. Attendees presented research and discussed new treatments in a collaborative setting…
Interstitial Lung Disease Remains Major a Diagnostic Challenge
Veracyte, Inc.recently presented four abstracts on current diagnostic challenges related to interstitial lung disease (ILD) and the potential for improved diagnostic procedures using novel genomic-based strategies. The abstracts were given at the Pulmonary Fibrosis Foundation’s PFF Summit 2015: From Bench to Bedside at the JW Marriott Hotel…
Pulmonary Fibrosis Patient’s Age May Affect Stem Cells’ Ability to Prevent Damage
A team of researchers report that a mouse’s age influences the ability of its mesenchymal stem cells to repair pulmonary fibrosis-induced damage, a finding with significant implications for stem cell therapies. The study, “Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis,”…
Living with IPF: Colin’s Story
Colin was diagnosed with idiopathic pulmonary fibrosis. Watch the video to see his testimony. Learn more about IPF : https://bit.ly/1QiRmr3…
IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial
Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the central nervous…
Last Week’s Top-3 Most Read Posts On Pulmonary Fibrosis
Read the articles here: 1. Potential Therapy for Severe Lung Disease Advances at aTyr Pharma 2. New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial 3. Genentech’s IPF Therapy Found to Improve Lung Function over Time…
